Drugs and mitochondrial diseases: 40 queries and answers

Bibliography

• DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656-68
   PubMed Web of Science ®Google Scholar
• Filosto M, Mancuso M. Mitochondrial diseases: a nosological update. Acta Neurol Scand 2007;115:211-21
   PubMed Web of Science ®Google Scholar
• Schaefer AM, McFarland R, Blakely EL, Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008;63:35-9
   PubMed Web of Science ®Google Scholar
• Khan SM, Smigrodzki RM, Swerdlow RH. Cell and animal models of mtDNA biology: progress and prospects. Am J Physiol Cell Physiol 2007;292:C658-69
   PubMed Web of Science ®Google Scholar
• King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-3
   PubMed Web of Science ®Google Scholar
• Couplan E, Aiyar RS, Kucharczyk R, A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA 2011;108:11989-94
   PubMed Web of Science ®Google Scholar
• Kawamata H, Tiranti V, Magrane J, adPEO mutations in ANT1 impair ADP-ATP translocation in muscle mitochondria. Hum Mol Genet 2011;20:2964-74
   PubMedGoogle Scholar
• Fulop L, Szanda G, Enyedi B, The effect of OPA1 on mitochondrial Ca(2) signaling. PLoS ONE 2011;6:e25199
   Google Scholar
• Longley MJ, Graziewicz MA, Bienstock RJ, Copeland WC. Consequences of mutations in human DNA polymerase gamma. Gene 2005;354:125-31
   PubMed Web of Science ®Google Scholar
• Li FY, Cuddon PA, Song J, Canine spongiform leukoencephalomyelopathy is associated with a missense mutation in cytochrome b. Neurobiol Dis 2006;21:35-42
   PubMed Web of Science ®Google Scholar
• Nakada K, Hayashi J. Transmitochondrial mice as models for mitochondrial DNA-based diseases. Exp Anim 2011;60:421-31
   PubMedGoogle Scholar
• Viscomi C, Burlina AB, Dweikat I, Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 2010;16:869-71
   PubMedGoogle Scholar
• Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;CD004426
   Google Scholar
• Koga Y, Povalko N, Katayama K, Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev 2012;34:87-91
   PubMed Web of Science ®Google Scholar
• Saito K, Kimura N, Oda N, Pyruvate therapy for mitochondrial DNA depletion syndrome. Biochim Biophys Acta 2011
   Google Scholar
• Orsucci D, Filosto M, Siciliano G, Mancuso M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev 2009;67:427-38
   PubMedGoogle Scholar
• Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med 2000;29:285-94
   PubMed Web of Science ®Google Scholar
• Sacconi S, Trevisson E, Salviati L, Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010;20:44-8
   PubMed Web of Science ®Google Scholar
• Cotan D, Cordero MD, Garrido-Maraver J, Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 2011;25:2669-87
   PubMed Web of Science ®Google Scholar
• Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-18
   PubMed Web of Science ®Google Scholar
• Glover EI, Martin J, Maher A, A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42:739-48
   PubMed Web of Science ®Google Scholar
• Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion 2007;7(Suppl):S72-7
   PubMedGoogle Scholar
• Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40:445-53
   PubMed Web of Science ®Google Scholar
• Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician 2005;72:1065-70
   PubMed Web of Science ®Google Scholar
• Land JM, Heales SJ, Duncan AJ, Hargreaves IP. Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency. Neurochem Res 2007;32:837-43
   PubMed Web of Science ®Google Scholar
• Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ. Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 2010;19:535-54
   PubMed Web of Science ®Google Scholar
• DiMauro S, Quinzii CM, Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 2007;117:587-9
   PubMed Web of Science ®Google Scholar
• Quinzii CM, Lopez LC, Naini A, Human CoQ10 deficiencies. Biofactors 2008;32:113-18
   PubMed Web of Science ®Google Scholar
• Lopez LC, Quinzii CM, Area E, Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS ONE 2010;5:e11897
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Sumner CJ, Penzak SR, Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8
   PubMed Web of Science ®Google Scholar
• Orsucci D, Mancuso M, Ienco EC, Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme q10 and its analogues. Curr Med Chem 2011;18:4053-64
   PubMed Web of Science ®Google Scholar
• Klopstock T, Yu-Wai-Man P, Dimitriadis K, A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134:2677-86
   PubMed Web of Science ®Google Scholar
• Carelli V, La Morgia C, Valentino ML, Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011;134:e188
   PubMed Web of Science ®Google Scholar
• Esposti MD, Ngo A, Ghelli A, The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 1996;330:395-400
   PubMed Web of Science ®Google Scholar
• Giorgio V, Petronilli V, Ghelli A, The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta 2012;1817:363-9
   PubMed Web of Science ®Google Scholar
• Enns GM, Kinsman SL, Perlman SL, Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012;105:91-102
   PubMed Web of Science ®Google Scholar
• Beg S, Javed S, Kohli K. Bioavailability enhancement of coenzyme Q10: an extensive review of patents. Recent Pat Drug Deliv Formul 2010;4:245-55
   PubMedGoogle Scholar
• Fetoni AR, Piacentini R, Fiorita A, Water-soluble Coenzyme Q10 formulation (Q-ter) promotes outer hair cell survival in a guinea pig model of noise induced hearing loss (NIHL). Brain Res 2009;1257:108-16
   PubMed Web of Science ®Google Scholar
• Cocheme HM, Kelso GF, James AM, Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 2007;7(Suppl):S94-102
   PubMed Web of Science ®Google Scholar
• James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005;280:21295-312
   PubMed Web of Science ®Google Scholar
• Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007;581:431-44
   PubMed Web of Science ®Google Scholar
• Ohnishi S, Okamura N, Sakamoto S, Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet 2008;23:293-303
   PubMedGoogle Scholar
• Nezu J, Tamai I, Oku A, Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999;21:91-4
   PubMed Web of Science ®Google Scholar
• Paddon-Jones D, Borsheim E, Wolfe RR. Potential ergogenic effects of arginine and creatine supplementation. J Nutr 2004;134:2888S-94S. discussion 95S
   PubMed Web of Science ®Google Scholar
• Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-9
   PubMed Web of Science ®Google Scholar
• Klopstock T, Querner V, Schmidt F, A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000;55:1748-51
   PubMed Web of Science ®Google Scholar
• Burke DG, Chilibeck PD, Parise G, Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab 2003;13:294-302
   PubMedGoogle Scholar
• Mayr JA, Zimmermann FA, Fauth C, Lipoic Acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am J Hum Genet 2011;89:792-7
   PubMed Web of Science ®Google Scholar
• Barbiroli B, Medori R, Tritschler HJ, Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995;242:472-7
   PubMed Web of Science ®Google Scholar
• Rodriguez MC, MacDonald JR, Mahoney DJ, Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35:235-42
   PubMed Web of Science ®Google Scholar
• Bugiani M, Lamantea E, Invernizzi F, Effects of riboflavin in children with complex II deficiency. Brain Dev 2006;28:576-81
   PubMed Web of Science ®Google Scholar
• Gempel K, Topaloglu H, Talim B, The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007;130:2037-44
   PubMed Web of Science ®Google Scholar
• Gerards M, van den Bosch BJ, Danhauser K, Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain 2011;134:210-19
   PubMedGoogle Scholar
• Lee DW, Selamoglu N, Lanciano P, Loss of a conserved tyrosine residue of cytochrome b induces reactive oxygen species production by cytochrome BC1. J Biol Chem 2011;286:18139-48
   PubMed Web of Science ®Google Scholar
• Vives-Bauza C, Gonzalo R, Manfredi G, Enhanced ROS production and antioxidant defenses in cybrids harbouring mutations in mtDNA. Neurosci Lett 2006;391:136-41
   PubMed Web of Science ®Google Scholar
• Hargreaves IP, Sheena Y, Land JM, Heales SJ. Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis 2005;28:81-8
   PubMed Web of Science ®Google Scholar
• Vergani L, Malena A, Sabatelli P, Cultured muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants. Brain 2007;130:2715-24
   PubMedGoogle Scholar
• Atkuri KR, Cowan TM, Kwan T, Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci USA 2009;106:3941-5
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, Logerfo A, Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 2010;257:774-81
   PubMed Web of Science ®Google Scholar
• Barbieri E, Sestili P. Reactive oxygen species in skeletal muscle signaling. J Signal Transduct 2012;2012:982794
   PubMedGoogle Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842-57
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Nyyssonen K, Tomasi A, Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res 2000;33:329-40
   PubMed Web of Science ®Google Scholar
• Soni MG, Thurmond TS, Miller ER III, Safety of vitamins and minerals: controversies and perspective. Toxicol Sci 2010;118:348-55
   PubMed Web of Science ®Google Scholar
• De Stefano N, Matthews PM, Ford B, Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45:1193-8
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Engelstad K, Wei Y, Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30
   PubMed Web of Science ®Google Scholar
• Liet JM, Pelletier V, Robinson BH, The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003;142:62-6
   PubMed Web of Science ®Google Scholar
• Yoneda M, Ikawa M, Arakawa K, In vivo functional brain imaging and a therapeutic trial of l-arginine in MELAS patients. Biochim Biophys Acta 2011
   Google Scholar
• Koga Y, Akita Y, Junko N, Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006;66:1766-9
   PubMed Web of Science ®Google Scholar
• Koga Y, Akita Y, Nishioka J, L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005;64:710-12
   PubMed Web of Science ®Google Scholar
• Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010;99:246-55
   PubMed Web of Science ®Google Scholar
• Koene S, Smeitink J. Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction. J Inherit Metab Dis 2011;34:315-25
   PubMedGoogle Scholar
• Ioannou N, Hargreaves IP, Allen G, Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: implications for mitochondrial cytopathies and neurodegenerative diseases. Biofactors 2010;36:468-73
   PubMedGoogle Scholar
• Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008;8:249-56
   PubMed Web of Science ®Google Scholar
• Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 2012;21:526-35
   PubMed Web of Science ®Google Scholar
• Viscomi C, Bottani E, Civiletto G, In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab 2011;14:80-90
   PubMed Web of Science ®Google Scholar
• Golubitzky A, Dan P, Weissman S, Screening for Active Small Molecules in Mitochondrial Complex I Deficient Patient's Fibroblasts, Reveals AICAR as the Most Beneficial Compound. PLoS ONE 2011;6:e26883
   PubMed Web of Science ®Google Scholar
• Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med 2004;37:304-17
   PubMed Web of Science ®Google Scholar
• Orsucci D, Calsolaro V, Mancuso M, Siciliano G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009;8:222-31
   PubMed Web of Science ®Google Scholar
• Haroon MF, Fatima A, Scholer S, Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol Dis 2007;28:237-50
   PubMed Web of Science ®Google Scholar
• Omar A, Johnson LN. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. Neurology 2007;68:1159-60
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, Calsolaro V, Tetracycline treatment in patients with progressive external ophthalmoplegia. Acta Neurol Scand 2011;124:417-23
   PubMed Web of Science ®Google Scholar
• Giordano C, Montopoli M, Perli E, Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain 2011;134:220-34
   PubMed Web of Science ®Google Scholar
• Voet NB, van der Kooi EL, Riphagen II, Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2010;CD003907
   Google Scholar
• Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 2010;19:1974-84
   PubMed Web of Science ®Google Scholar
• DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 2007;27:125-37
   PubMed Web of Science ®Google Scholar
• Tachibana M, Sparman M, Sritanaudomchai H, Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009;461:367-72
   PubMed Web of Science ®Google Scholar
• Finsterer J. Treatment of central nervous system manifestations in mitochondrial disorders. Eur J Neurol 2011;18:28-38
   PubMed Web of Science ®Google Scholar
• Finsterer J. Management of mitochondrial stroke-like-episodes. Eur J Neurol 2009;16:1178-84
   PubMedGoogle Scholar
• Rossi FH, Okun M, Yachnis A, Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002;8:313-15
   PubMedGoogle Scholar
• Visser NA, Braun KP, Leijten FS, Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011;258:218-22
   PubMed Web of Science ®Google Scholar
• Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010;33:138-51
   PubMed Web of Science ®Google Scholar
• Mancuso M, Galli R, Pizzanelli C, Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006;243:97-9
   PubMed Web of Science ®Google Scholar
• Gibbs JE, Walker MC, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006;47:469-78
   PubMed Web of Science ®Google Scholar
• Tzoulis C, Engelsen BA, Telstad W, The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129:1685-92
   PubMed Web of Science ®Google Scholar
• Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007;22:105-9
   PubMed Web of Science ®Google Scholar
• Chiyonobu T, Noda R, Yoshida M, Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 2008;30:430-3
   PubMed Web of Science ®Google Scholar
• Aldakkak M, Stowe DF, Chen Q, Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release. Cardiovasc Res 2008;77:406-15
   PubMed Web of Science ®Google Scholar
• Araujo IM, Ambrosio AF, Leal EC, Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004;45:1498-505
   PubMed Web of Science ®Google Scholar
• Costa C, Belcastro V, Tozzi A, Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 2008;28:8040-52
   PubMed Web of Science ®Google Scholar
• Mirza NS, Alfirevic A, Jorgensen A, Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21:297-302
   PubMed Web of Science ®Google Scholar
• Belotti EA, Taddeo I, Ragazzi M, Chronic impact of topiramate on acid-base balance and potassium in childhood. Eur J Paediatr Neurol 2010;14:445-8
   PubMedGoogle Scholar
• Shiber JR. Severe non-anion gap metabolic acidosis induced by topiramate: a case report. J Emerg Med 2010;38:494-6
   PubMedGoogle Scholar
• Lu J, Li Z, Zhu Y, Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion 2010;10:380-90
   PubMed Web of Science ®Google Scholar
• Rydzanicz M, Wrobel M, Pollak A, Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochem Biophys Res Commun 2010;395:116-21
   PubMedGoogle Scholar
• Qian Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 2009;53:4612-18
   PubMed Web of Science ®Google Scholar
• Hobbie SN, Akshay S, Kalapala SK, Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008;105:20888-93
   PubMed Web of Science ®Google Scholar
• Cope TE, McFarland R, Schaefer A. Rapid-onset, linezolid-induced lactic acidosis in MELAS. Mitochondrion 2011;11:992-3
   PubMed Web of Science ®Google Scholar
• Zoraster RM, Rison RA. Severe lactic acidosis secondary to minocycline in a teenager with infectious mononucleosis and mitochondrial myopathy. Clin Neurol Neurosurg 2008;110:627-30
   PubMedGoogle Scholar
• Kupsch K, Hertel S, Kreutzmann P, Impairment of mitochondrial function by minocycline. FEBS J 2009;276:1729-38
   PubMed Web of Science ®Google Scholar
• Jones CN, Miller C, Tenenbaum A, Antibiotic effects on mitochondrial translation and in patients with mitochondrial translational defects. Mitochondrion 2009;9:429-37
   PubMedGoogle Scholar
• Viollet B, Guigas B, Sanz Garcia N, Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70
   PubMed Web of Science ®Google Scholar
• Protti A, Russo R, Tagliabue P, Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care 2010;14:R22
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7
   PubMed Web of Science ®Google Scholar
• Lamperti C, Naini AB, Lucchini V, Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62:1709-12
   PubMed Web of Science ®Google Scholar
• Paiva H, Thelen KM, Van Coster R, High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60-8
   PubMed Web of Science ®Google Scholar
• Schick BA, Laaksonen R, Frohlich JJ, Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81:650-3
   PubMed Web of Science ®Google Scholar
• Tay SK, Dimauro S, Pang AY, Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol 2008;39:426-8
   PubMed Web of Science ®Google Scholar
• Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol 2009;107:8-16
   PubMed Web of Science ®Google Scholar
• Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003;27:142-56
   PubMed Web of Science ®Google Scholar
• Pfeffer G, Cote HC, Montaner JS, Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009;73:71-2
   PubMed Web of Science ®Google Scholar
• Mastaglia FL, Needham M. Update on Toxic Myopathies. Curr Neurol Neurosci Rep 2012;12:54-61
   PubMed Web of Science ®Google Scholar
• Seok JI, Lee DK, Lee CH, Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-6
   PubMed Web of Science ®Google Scholar
• Muravchick S. Clinical implications of mitochondrial disease. Adv Drug Deliv Rev 2008;60:1553-60
   PubMedGoogle Scholar
• Hanley PJ, Ray J, Brandt U, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 2002;544:687-93
   PubMed Web of Science ®Google Scholar
• Vanlander AV, Jorens PG, Smet J, Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome. Acta Anaesthesiol Scand 2012
   PubMedGoogle Scholar
• Morgan PG, Hoppel CL, Sedensky MM. Mitochondrial defects and anesthetic sensitivity. Anesthesiology 2002;96:1268-70
   PubMedGoogle Scholar
• Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011;107:48-56
   PubMed Web of Science ®Google Scholar
• Parikh S, Saneto R, Falk MJ, A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009;11:414-30
   PubMed Web of Science ®Google Scholar
• Battaglia V, Salvi M, Toninello A. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J Biol Chem 2005;280:33864-72
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005;42:110-16
   PubMed Web of Science ®Google Scholar
• Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. Br J Clin Pharmacol 2011;71:20-8
   PubMed Web of Science ®Google Scholar
• Maharaj H, Maharaj DS, Daya S. Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. Life Sci 2006;78:2438-43
   PubMed Web of Science ®Google Scholar
• Hadzimichalis NM, Baliga SS, Golfetti R, Acetaminophen-mediated cardioprotection via inhibition of the mitochondrial permeability transition pore-induced apoptotic pathway. Am J Physiol Heart Circ Physiol 2007;293:H3348-55
   Google Scholar
• Baliga SS, Jaques-Robinson KM, Hadzimichalis NM, Acetaminophen reduces mitochondrial dysfunction during early cerebral postischemic reperfusion in rats. Brain Res 2010;1319:142-54
   PubMedGoogle Scholar
• Cordero MD, Moreno-Fernandez AM, Gomez-Skarmeta JL, Coenzyme Q10 and alpha-tocopherol protect against amitriptyline toxicity. Toxicol Appl Pharmacol 2009;235:329-37
   PubMed Web of Science ®Google Scholar
• Moreno-Fernandez AM, Cordero MD, Garrido-Maraver J, Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res 2011
   PubMedGoogle Scholar
• Morris CG, Low J. Metabolic acidosis in the critically ill: part 2. Causes and treatment. Anaesthesia 2008;63:396-411
   PubMed Web of Science ®Google Scholar
• Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010;6:274-85
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, Calsolaro V, Coenzyme Q10 and Neurological Diseases. Pharmaceuticals 2009;2:134-49
   Google Scholar